Senior Vice President, Chemistry and Non- Clinical Development · ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Zhen Li

A named executive officer of ARROWHEAD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,085,993

Salary $150,257Stock awards $931,500

FY2018: $686,124

6th of 6 named executive officers at Arrowhead Pharmaceuticals by FY2019 total.

6 named officers on file for ARROWHEAD PHARMACEUTICALS, FY2019

Zhen Li’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • ARWR’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARROWHEAD PHARMACEUTICALS’s whole pay program stands against its peers

  • ARROWHEAD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARWR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 28, 2020 (DEF 14A).

Free

Get Zhen Li’s full pay file as a PDF — free

More than this page: up to 10 years of Zhen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Zhen Li compensation by year

ARROWHEAD PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as ARROWHEAD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$237,930$247,448$287,462$150,257
Bonus$0$0$0$0
Stock awards$0$131,750$239,200$931,500
Option awards$230,479$0$0$0
Non-equity incentive$72,072$120,000$150,000$0
Pension and deferred compensation$0$0$0$0
All other$10,173$6,798$9,462$4,236
Total$550,654$505,996$686,124$1,085,993

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARROWHEAD PHARMACEUTICALS, INC. DEF 14A filed January 28, 2020, accession 0001193125-20-017001, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARROWHEAD PHARMACEUTICALS, INC. filed document, accession 0001193125-20-017001. Every figure is read from that document and cited to the page and table it appears in. Filed January 28, 2020.

$551K
$506K
$686K
$1.1M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU85,000$1,629,450—
RSU65,000$1,246,050—
Option3,750—$5.45
Option16,667—$6.15

Per the Outstanding Equity Awards at Fiscal Year-End table in ARROWHEAD PHARMACEUTICALS, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

ARROWHEAD PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Bruce GivenFormer Chief Operating Officer$3,958,759
Christopher AnzalonePresident and Chief Executive Officer$2,216,264
Kenneth MyszkowskiChief Financial Officer$1,741,549
Patrick O’BrienGeneral Counsel$1,552,943
James HamiltonVP Discovery and Translational Medicine$1,218,156
Zhen Li · this pageSenior Vice President, Chemistry and Non- Clinical Development$1,085,993

The full ARROWHEAD PHARMACEUTICALS compensation record

free company brief

This page is one person within ARROWHEAD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARROWHEAD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARROWHEAD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Zhen Li's compensation dossier · One-time report. No refunds.